Retrospective Comparison of Initial vs. Subsequent Simultaneous Side-by-Side Stenting with Uncovered Metal Stents during Endoscopic Retrograde Cholangiopancreatography for Unresectable Malignant Hilar Biliary Obstructions.
Koji Takahashi, Hiroshi Ohyama, Motoyasu Kan, Mayu Ouchi, Hiroki Nagashima, Kohichiroh Okitsu, Izumi Ohno, Naoya Kato
{"title":"Retrospective Comparison of Initial vs. Subsequent Simultaneous Side-by-Side Stenting with Uncovered Metal Stents during Endoscopic Retrograde Cholangiopancreatography for Unresectable Malignant Hilar Biliary Obstructions.","authors":"Koji Takahashi, Hiroshi Ohyama, Motoyasu Kan, Mayu Ouchi, Hiroki Nagashima, Kohichiroh Okitsu, Izumi Ohno, Naoya Kato","doi":"10.15403/jgld-5933","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>This study aimed to evaluate the efficacy and safety of transpapillary simultaneous side-by-side (SBS) stenting using uncovered self-expandable metal stents (UCSEMSs) at the initial endoscopic retrograde cholangiopancreatography (ERCP) for unresectable malignant hilar biliary obstruction (UMHBO).</p><p><strong>Methods: </strong>A total of 67 patients with UMHBO who underwent simultaneous SBS stenting at our institution were retrospectively divided into two groups: the SBS stenting at the initial ERCP group (n=13) and the SBS stenting at the subsequent ERCP group (n=54). Clinical outcomes were compared between the groups.</p><p><strong>Results: </strong>There were no significant differences between the SBS stenting at the initial ERCP group and the SBS stenting at the subsequent ERCP group in procedural time (median: 50 vs. 40 minutes, p=0.31), functional success rate (69.2% vs. 83.3%, p=0.25), adverse event rate (30.8% vs. 14.8%, p=0.18), recurrent biliary obstruction (RBO) rate (23.1% vs. 38.9%, p=0.29), technical success rate of re-intervention (100% vs. 90.5%, p=0.58), cumulative time to RBO (not reached vs. 252 days, p=0.80), or median overall survival (73 vs. 212 days, p=0.12).</p><p><strong>Conclusions: </strong>Simultaneous SBS stenting using UCSEMSs at the initial ERCP is a safe and effective strategy for managing UMHBO, with outcomes comparable to those of SBS stenting performed at the subsequent ERCP.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"214-219"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastrointestinal and liver diseases : JGLD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15403/jgld-5933","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: This study aimed to evaluate the efficacy and safety of transpapillary simultaneous side-by-side (SBS) stenting using uncovered self-expandable metal stents (UCSEMSs) at the initial endoscopic retrograde cholangiopancreatography (ERCP) for unresectable malignant hilar biliary obstruction (UMHBO).
Methods: A total of 67 patients with UMHBO who underwent simultaneous SBS stenting at our institution were retrospectively divided into two groups: the SBS stenting at the initial ERCP group (n=13) and the SBS stenting at the subsequent ERCP group (n=54). Clinical outcomes were compared between the groups.
Results: There were no significant differences between the SBS stenting at the initial ERCP group and the SBS stenting at the subsequent ERCP group in procedural time (median: 50 vs. 40 minutes, p=0.31), functional success rate (69.2% vs. 83.3%, p=0.25), adverse event rate (30.8% vs. 14.8%, p=0.18), recurrent biliary obstruction (RBO) rate (23.1% vs. 38.9%, p=0.29), technical success rate of re-intervention (100% vs. 90.5%, p=0.58), cumulative time to RBO (not reached vs. 252 days, p=0.80), or median overall survival (73 vs. 212 days, p=0.12).
Conclusions: Simultaneous SBS stenting using UCSEMSs at the initial ERCP is a safe and effective strategy for managing UMHBO, with outcomes comparable to those of SBS stenting performed at the subsequent ERCP.
背景和目的:本研究旨在评估在初始内镜逆行胆管造影(ERCP)中使用无盖自膨胀金属支架(UCSEMSs)进行经毛细血管同时并排(SBS)支架治疗不可切除的恶性肝门胆道梗阻(UMHBO)的有效性和安全性。方法:回顾性将67例在我院同时行SBS支架置入的UMHBO患者分为两组:首次ERCP组SBS支架置入组(n=13)和随后ERCP组(n=54)。比较两组临床结果。结果:初始ERCP组SBS支架置入与后续ERCP组SBS支架置入在手术时间上无显著差异(中位数:50 vs. 40分钟,p=0.31),功能成功率(69.2% vs. 83.3%, p=0.25),不良事件发生率(30.8% vs. 14.8%, p=0.18),复发性胆道梗阻(RBO)率(23.1% vs. 38.9%, p=0.29),再干预技术成功率(100% vs. 90.5%, p=0.58),累计到RBO时间(未达到vs. 252天,p=0.80),或中位总生存期(73 vs. 212天,p=0.12)。结论:在最初的ERCP中使用UCSEMSs同时置入SBS支架是一种安全有效的治疗UMHBO的策略,其结果与在随后的ERCP中使用SBS支架的结果相当。